Protein kinase C isozymes as potential therapeutic targets in immune disorders - PubMed (original) (raw)
Review
Protein kinase C isozymes as potential therapeutic targets in immune disorders
Matthew R Lee et al. Expert Opin Ther Targets. 2008 May.
Abstract
Background: Members of the protein kinase C (PKC) family are key signalling mediators in immune responses, and pharmacological inhibition of PKCs may be useful for treating immune-mediated diseases.
Objective: To review and discuss the insights gained so far into various PKC isozymes and the therapeutic potential and challenges of developing PKC inhibitors for immune disorder therapy.
Methods: A literature review of the role of PKCs in immune cell signalling and recent studies describing immune functions associated with PKC isozyme deficiency in relevant mouse disease models, followed by specific case studies of current and potential therapeutic strategies targeting PKCs.
Results/conclusion: There is vast amount of data supporting PKC isozymes as attractive drug targets for certain immune disorders. Although the development of specific PKC isozyme inhibitors has been challenging, some progress has been made. It remains to be seen if broad-scale or isozyme-selective inhibition of PKC will have clinical efficacy.
Similar articles
- PKC inhibitors: potential in T cell-dependent immune diseases.
Baier G, Wagner J. Baier G, et al. Curr Opin Cell Biol. 2009 Apr;21(2):262-7. doi: 10.1016/j.ceb.2008.12.008. Epub 2009 Feb 3. Curr Opin Cell Biol. 2009. PMID: 19195860 Review. - Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation.
Csukai M, Mochly-Rosen D. Csukai M, et al. Pharmacol Res. 1999 Apr;39(4):253-9. doi: 10.1006/phrs.1998.0418. Pharmacol Res. 1999. PMID: 10208754 Review. - PKC isozymes in chronic cardiac disease: possible therapeutic targets?
Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D. Churchill E, et al. Annu Rev Pharmacol Toxicol. 2008;48:569-99. doi: 10.1146/annurev.pharmtox.48.121806.154902. Annu Rev Pharmacol Toxicol. 2008. PMID: 17919087 Review. - Lung disease and PKCs.
Dempsey EC, Cool CD, Littler CM. Dempsey EC, et al. Pharmacol Res. 2007 Jun;55(6):545-59. doi: 10.1016/j.phrs.2007.04.010. Epub 2007 Apr 29. Pharmacol Res. 2007. PMID: 17582782 Review.
Cited by
- Developmental protein kinase C hyper-activation results in microcephaly and behavioral abnormalities in zebrafish.
Liu T, Shi Y, Chan MTV, Peng G, Zhang Q, Sun X, Zhu Z, Xie Y, Sham KWY, Li J, Liu X, Ho IHT, Gin T, Lu Z, Wu WKK, Cheng CHK. Liu T, et al. Transl Psychiatry. 2018 Oct 23;8(1):232. doi: 10.1038/s41398-018-0285-5. Transl Psychiatry. 2018. PMID: 30352990 Free PMC article. - Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes.
Boudreault PL, Mattler JK, Wender PA. Boudreault PL, et al. Tetrahedron Lett. 2015 Jun;56(23):3423-3427. doi: 10.1016/j.tetlet.2015.01.126. Tetrahedron Lett. 2015. PMID: 26034334 Free PMC article. - A unified approach to the important protein kinase inhibitor balanol and a proposed analogue.
Saha T, Maitra R, Chattopadhyay SK. Saha T, et al. Beilstein J Org Chem. 2013 Dec 19;9:2910-5. doi: 10.3762/bjoc.9.327. eCollection 2013 Dec 19. Beilstein J Org Chem. 2013. PMID: 24454570 Free PMC article. - Notch and PKC are involved in formation of the lateral region of the dorso-ventral axis in Drosophila embryos.
Tremmel DM, Resad S, Little CJ, Wesley CS. Tremmel DM, et al. PLoS One. 2013 Jul 4;8(7):e67789. doi: 10.1371/journal.pone.0067789. Print 2013. PLoS One. 2013. PMID: 23861806 Free PMC article. - Down-regulation of protein kinase Cδ inhibits inducible nitric oxide synthase expression through IRF1.
Leppänen T, Korhonen R, Laavola M, Nieminen R, Tuominen RK, Moilanen E. Leppänen T, et al. PLoS One. 2013;8(1):e52741. doi: 10.1371/journal.pone.0052741. Epub 2013 Jan 9. PLoS One. 2013. PMID: 23326354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical